Henry Schein Inc (HSIC) is a publicly traded Healthcare sector company. As of May 20, 2026, HSIC trades at $73.23 with a market cap of $8.28B and a P/E ratio of 23.93. HSIC moved +0.43% today. Year to date, HSIC is -6.76%; over the trailing twelve months it is +0.14%. Its 52-week range spans $60.56 to $89.29. Analyst consensus is buy with an average price target of $87.43. Rallies surfaces HSIC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Henry Schein slides 3% as Mizuho trims price target after Q1 results: Henry Schein shares fell on May 6, 2026 as investors digested Q1 results and fresh sell-side caution, including a Mizuho price-target cut to $82. The pullback comes a day after the company reported Q1 revenue of about $3.37 billion and lifted FY2026 EPS guidance to $5.23–$5.37.
| Metric | Value |
|---|---|
| Price | $73.23 |
| Market Cap | $8.28B |
| P/E Ratio | 23.93 |
| EPS | $3.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $89.29 |
| 52-Week Low | $60.56 |
| Volume | 1.07M |
| Avg Volume | 0 |
| Revenue (TTM) | $12.67B |
| Net Income | $398.00M |
| Gross Margin | 31.69% |
16 analysts cover HSIC: 0 strong buy, 8 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $87.43.